GSK3 and p53-is there a link in Alzheimer's disease?

被引:65
|
作者
Proctor, Carole J. [1 ]
Gray, Douglas A. [1 ,2 ,3 ]
机构
[1] Univ Newcastle, Inst Ageing & Hlth, Ctr Integrated Syst Biol Ageing & Nutr, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England
[2] Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada
[3] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada
来源
MOLECULAR NEURODEGENERATION | 2010年 / 5卷
基金
加拿大健康研究院;
关键词
GLYCOGEN-SYNTHASE KINASE-3-BETA; TAU-PROTEIN; PHOSPHORYLATED TAU; CELL-SURVIVAL; DEGRADATION; PROTEASOME; NEURODEGENERATION; ACCUMULATION; AGGREGATION; GSK3-BETA;
D O I
10.1186/1750-1326-5-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Recent evidence suggests that glycogen synthase kinase-3 beta (GSK3 beta) is implicated in both sporadic and familial forms of Alzheimer's disease. The transcription factor, p53 also plays a role and has been linked to an increase in tau hyperphosphorylation although the effect is indirect. There is also evidence that GSK3 beta and p53 interact and that the activity of both proteins is increased as a result of this interaction. Under normal cellular conditions, p53 is kept at low levels by Mdm2 but when cells are stressed, p53 is stabilised and may then interact with GSK3 beta. We propose that this interaction has an important contribution to cellular outcomes and to test this hypothesis we developed a stochastic simulation model. Results: The model predicts that high levels of DNA damage leads to increased activity of p53 and GSK3 beta and low levels of aggregation but if DNA damage is repaired, the aggregates are eventually cleared. The model also shows that over long periods of time, aggregates may start to form due to stochastic events leading to increased levels of ROS and damaged DNA. This is followed by increased activity of p53 and GSK3 beta and a vicious cycle ensues. Conclusions: Since p53 and GSK3 beta are both involved in the apoptotic pathway, and GSK3 beta overactivity leads to increased levels of plaques and tangles, our model might explain the link between protein aggregation and neuronal loss in neurodegeneration.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] GSK3 and p53 - is there a link in Alzheimer's disease?
    Carole J Proctor
    Douglas A Gray
    Molecular Neurodegeneration, 5
  • [2] The GSK3 hypothesis of Alzheimer's disease
    Hooper, Claudie
    Killick, Richard
    Lovestone, Simon
    JOURNAL OF NEUROCHEMISTRY, 2008, 104 (06) : 1433 - 1439
  • [3] GSK3 and Alzheimer's disease: facts and fiction
    Kremer, Anna
    Louis, Justin V.
    Jaworski, Tomasz
    Van Leuven, Fred
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2011, 4
  • [4] GSK3 in Alzheimer's Disease: Mind the Isoforms
    Ma, Tao
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 39 (04) : 707 - 710
  • [5] Role of GSK3 in Alzheimer disease
    Bhat, R
    Berg, S
    NEUROBIOLOGY OF AGING, 2006, 27 : S3 - S3
  • [6] The role of GSK3 in Alzheimer disease
    Hernandez, Felix
    Gomez de Barreda, Elena
    Fuster-Matanzo, Almudena
    Goni-Oliver, Paloma
    Lucas, Jose J.
    Avila, Jesus
    BRAIN RESEARCH BULLETIN, 2009, 80 (4-5) : 248 - 250
  • [7] GSK3β and Tau Protein in Alzheimer's Disease and Epilepsy
    Toral-Rios, Danira
    Pichardo-Rojas, Pavel S.
    Alonso-Vanegas, Mario
    Campos-Pena, Victoria
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2020, 14
  • [8] GSK3 and Tau: Two Convergence Points in Alzheimer's Disease
    Hernandez, Felix
    Lucas, Jose J.
    Avila, Jesus
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 33 : S141 - S144
  • [9] GSK3β signalling:: Casting a wide net in Alzheimer's disease
    Bhat, RV
    Budd, SL
    NEUROSIGNALS, 2002, 11 (05) : 251 - 261
  • [10] GSK3: A potential target and pending issues for treatment of Alzheimer's disease
    Zhao, Jiahui
    Wei, Mengying
    Guo, Minsong
    Wang, Mengyao
    Niu, Hongxia
    Xu, Tengfei
    Zhou, Yuan
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (07)